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Abstract: A new Ru(II) bipyridyl complex with O4-hydrogenpyridine-2,4- 
-dicarboxylate was synthesized and characterized by IR, NMR and mass spec-
trometry, X-ray diffraction analysis and elemental analysis. The electrochem-
ical characteristics of the complex were investigated by cyclic voltammetry, 
revealing Ru(II)/Ru(III) electron transfer in the positive range of potentials. On 
the opposite potential side, multiple partially reversible peaks were dominant, 
representing subsequent reductions of the bulky bipyridyl moiety. The cyto-
toxic activity of the complex was tested in two human cancer cell lines: A549 
(lung cancer) and K562 (leukemia) as well as non-tumor MRC-5 cells, by MTT 
assays. The IC50 values were > 300 and 177.63±2.28 μM for the A549 and 
K562 cells, respectively. 
Keywords: metal complex; characterization; X-ray; redox properties; biological 
study. 
INTRODUCTION 
The search for efficient antitumor agents is a topic of prime interest in the 
field of medicinal chemistry.1–3 Despite the fact that metal complexes are key- 
-components in the treatment of some tumors, there is currently a lack of suitable 
drugs. Novel, more efficient and less toxic substances, capable of treating cancers 
are therefore considered highly desirable compounds. While the clinical success 
of platinum complexes is indisputable,4,5 due to the many side effects of these 
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drugs (nerve damage, hair loss and nausea) and cellular resistance, thousands of 
new platinum and non-platinum complexes were synthesized, in order to find a 
more suitable antitumor drug.6,7 Coordination compounds allow a very diverse 
platform for drug design. In addition to various oxidation states of metals, metal 
complexes have different geometries and coordination numbers that ensure the 
fine-tuning of their chemical reactivity.8,9 Ruthenium compounds are particularly 
favored because of their tendency to cause fewer side effects compared to pla-
tinum drugs and their physicochemical properties, which include chemical sta-
bility and structural diversity. 
Ruthenium compounds have shown highly promising biological activity 
with the two structurally similar compounds KP1019 and NAMI-A, which are 
under evaluation in phase II clinical trials (KP1019 is active against primary can-
cers whereas NAMI-A is active against secondary tumor cells).8,10–13  
Picolinic acid plays an important role as a component of specific enzymes 
and as an active agent in a number of drugs. For example, 2,4-pyridinedicar-
boxylic acid showed immuno-suppressive and fibro-suppressive properties,14 
while 2,4-, 2,5- and 2,6-pyridinedicarboxylic acid were included into inhibition 
or activation of some metalloenzymes.15,16 
Iron(III) complexes with 2,6-pyridinedicarboxylates were synthesized and 
their significant role in electron transfer in some models of biological systems 
was documented in several papers.17,18 In addition, these molecules were recog-
nized as specific molecular tools in DNA cleavage tests.19  
In the last two decades, numerous organo-ruthenium(II) complexes 
containing the p-cymene moiety and a pyridine derivative, coordinating in a 
monodentate or bidentate manner, were synthesized and their in vitro antipro-
liferative activity was investigated in the numerous cell lines. The obtained 
results indicated that these compounds exhibit moderate antitumor activity with 
one complicated mechanism of action, involving extra and intra-cellular pro-
cesses, which is quite different compared to the classical platinum drugs.20–22 
In this work, the synthesis and full characterization of a new ruthenium(II) 
bipyridyl complex, [RuL(bpy)2]PF6·0.5H2O (1), where L represents O4-hydro-
genpyridine-2,4-dicarboxylate, are described. The antitumor potential of the syn-
thesized compound and its electrochemical profile are also reported. 
EXPERIMENTAL 
Materials and measurements 
All experiments were performed under atmospheric conditions with commercially avail-
able chemicals and solvents used as received. In particular, 2,4-pyridinedicarboxylic acid was 
purchased from Sigma–Aldrich. The starting complex, [RuCl2(bpy)2] was synthesized accord-
ing to a previously described, but slightly modified synthetic route.23,24 
Elemental analysis was performed on an Elemental Vario EL III microanalyzer. A 
Nicolet 6700 FT-IR spectrometer was used for recording the infrared spectrum. The signal 
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intensities are reported in wavenumbers and denoted by the following abbreviations: vs = very 
strong, s = strong, m = medium and w = weak. An LTQ Orbitrap XL mass spectrometer 
(Heated ESI) was used for recording the mass spectra in acetonitrile (HPLC grade) in the 
positive mode. The obtained peaks were assigned and interpreted according to the dimen-
sionless mass/charge ratio. The 1H-NMR spectrum was recorded using a Bruker Avance III 
500 spectrometer with TMS as the reference. For proton assignments, following abbreviations 
were used: (b)s = (broad) singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, 
p = pentet, m = multiplet and Ar = aromatic protons. A rough estimation of the melting points 
of the compound was realized using an electrothermal melting point apparatus. Analytical and 
spectral data of the compound are given in Supplementary material to this paper. 
Synthesis of the complex 
For the preparation of complex 1, [RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in 
ethanol (15 mL) and stirred for 20 min at 40 °C. 2,4-Pyridinedicarboxylic acid (35 mg, 0.21 
mmol) was dissolved in a small volume of ethanol (5 mL) and added to the solution of the 
starting complex. The reaction mixture was immediately stirred under reflux for 3 h and 
afterwards left to cool to room temperature. After the addition of an equimolar amount of 
NH4PF6 (33.7 mg, 0.21 mmol), a dark red precipitate was isolated by filtration. The crude 
product was washed with a small amount of water and diethyl ether. 
Single crystal X-ray diffraction 
For the reported structure, X-ray intensity data were collected, at 100 K, on an Agilent 
Supernova dual source (Cu at zero) diffractometer equipped with an Atlas CCD detector using 
ω scans and CuKα (λ = 1.54184 Å) radiation. The images were interpreted and integrated with 
the CrysAlisPro program (Rigaku Oxford Diffraction, 2015).25 Using Olex2,26 the structure 
was solved by direct methods using the ShelXS structure solution program and refined by full-
matrix least-squares on F2 using the ShelXL program package.27,28 Non-hydrogen atoms were 
anisotropically refined and the hydrogen atoms were refined in the riding mode. Isotropic 
temperature factors were fixed at 1.2 times U(eq) of the parent atoms. The hydrogen atoms of 
the solvent water molecule and the O4-hydrogenpyridine-2,4-dicarboxylate carboxyl group 
were located from a difference Fourier electron density map and restrained refined with 
isotropic temperature factors fixed at 1.5 times U(eq) of the parent atoms.  
Electrochemical measurements 
Electrochemical measurements were performed with a CHI-760B instrument at room 
temperature. The voltammetric measurement was performed in a three-electrode cell, which 
consisted of a glassy carbon electrode (Model 6.1204.300), an auxiliary platinum electrode 
with large surface area (model CHI221, cell top including a platinum wire counter electrode) 
and an Ag/AgCl reference electrode (model CHI111). For the purpose of experiments, 1.0 
mM solution of the synthesized complex was prepared in DMSO and TBAP was added as a 
supporting electrolyte. Cyclic voltammograms for 1 were obtained at 25, 50, 100, 150, 200 
and 300 mV s-1. 
Cytotoxicity 
Reagents and cell cultures. Human alveolar basal adenocarcinoma (A549), human chro-
nic myelogenous leukaemia (K562) and human fetal lung fibroblast (MRC-5) cell lines were 
maintained as a monolayer culture in the Roswell Park Memorial Institute (RPMI) 1640 
nutrient medium (Sigma–Aldrich). The nutrient medium was supplemented with 10 % heat- 
-deactivated fetal calf serum (FCS, Sigma–Aldrich), 4-(2-hydroxyethyl)piperazine-1-ethane-
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sulfonic acid (HEPES, 25 mM), penicillin (100 units mL-1), streptomycin (200 μg mL-1) and 
L-glutamine (3 mM). The cells were maintained as a monolayer culture in tissue culture flasks 
(Thermo Scientific Nunc™), in an incubator at 37 °C, in a humidified atmosphere composed 
of 5 % CO2. 
MTT cytotoxicity assay. The drug-induced cytotoxicity was determined using the 3-(4,5- 
-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma–Aldrich) assay.29 Cells 
were seeded into 96-well cell culture plates (Thermo Scientific Nunc™), in number of 5000 
(K562), 7000 (MRC-5) and 8000 cells per well (A549), in 100 µL of culture medium. After 
24 h of growth, the cells were exposed to the serial dilutions of the tested agent. Stock 
solutions were prepared immediately prior to use by dissolving in dimethyl sulfoxide 
(DMSO), so that the DMSO content did not exceed 1 vol. %. The antiproliferative effect of 
the complex was evaluated in a range of concentrations up to 300 µM, for 72 h of continuous 
drug action. After the treatment, 20 µl of MTT solution, 5 mg mL-1 in phosphate buffer 
solution (PBS), pH 7.2, was added to each well. The samples were incubated for 4 h at 37 °C 
with 5 % CO2 under a humidified atmosphere. Formazan crystals were dissolved in 100 µL of 
10 % sodium dodecyl sulfate (SDS). The absorbance was recorded at a wavelength of 570 nm 
using a microplate reader (ThermoLabsystems Multiskan EX 200e240 V) after 24 h The IC50 
value (µM) was defined as the concentration of the drug that produced 50 % inhibition of cell 
survival, and was determined based on cell survival diagrams. 
RESULTS AND DISCUSSION 
Synthesis 
The main subject of the study was the synthesis and full characterization of a 
new ruthenium(II) bipyridyl complex with 2,4-pyridinedicarboxylic acid 
(Scheme 1). The obtained compound was air stable and showed no traces of 
decomposition.  
 
Scheme 1. Synthesis of the [RuL(bpy)2]PF6 complex. 
Spectroscopy 
The IR spectrum of the synthesized complex generally revealed an asym-
metric stretching vibration located around 1605 cm–1 that originated from the 
coordinated carboxylate group. The coordination of the metal center via oxygen 
is suggested by comparison to the band of the free carboxylic group at ≈1700 
cm–1 in the spectrum of the ligand. The intensive band found at 840 cm–1 was 
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assigned to C–H stretching modes. In the ESI-MS spectrum of the complex 
recorded in acetonitrile, the [M+–PF6–] signal was detected. 
In the 1H-NMR spectrum of the complex, all the aromatic protons were 
detected in the range of 7.39–8.84 ppm, which belong to aromatic protons origin-
ating from the pyridine and bipyridine moieties. Carboxylic protons were not 
detected because the co-ligand was coordinated to ruthenium through the oxygen 
atom of the carboxylic group in position 2 of the pyridine ring, while the car-
boxylic group in position 4 was deprotonated in DMSO. 
Crystal data for compound  
Compound 1 crystallized in the centro-symmetric space group P21/n, with 
one [RuL(bpy)2]PF6 complex in the asymmetric unit, together with one water 
solvent molecule (Fig. 1). The Ru(II) ion is octahedrally coordinated by four nit-
rogen atoms from the two bipyridine ligands, and one nitrogen and one oxygen 
atom from the O4-hydrogenpyridine-2,4-dicarboxylate. In fact, while the coor-
dinating carboxyl group in position 2 of the 2,4-dicarboxylic acid ligand is depro-
tonated, the other carboxyl group in position 4 is clearly protonated. The Ru(II)– 
–Nbpy distances are in the range of 2.031(4)–2.055(4) Å, while the Ru(II)–NL 
and Ru(II)–OL distances are 2.049(3) Å and 2.090(3) Å, respectively. The 
N–Ru–N/O angles vary between 79.07(13)° and 99.05(13)°. 
 
Fig. 1. Asymmetric unit of the crystal structure of 1, consisting of one [RuL(bpy)2]PF6 com-
plex and one water solvent molecule, with atom-labeling scheme of the heteroatoms (except 
for PF6-). Thermal displacement ellipsoids are drawn at the 50 % probability level. 
In the crystal packing, hydrogen bonds are formed between the O4-hydro-
genpyridine-2,4-dicarboxylate groups and the water solvent molecule. Each 
water molecule forms a hydrogen bond with the deprotonated carboxylic group 
(O5(–H5A)∙∙∙O2 = 2.692(4) Å) and with the protonated carboxylic groups of two 
symmetry-equivalent Ru(II) complexes (O5(–H5B)∙∙∙O3i = 2.822(4) Å and 
O5∙∙∙(H4–)O4ii = 2.552(4) Å; symmetry codes: i) 1/2+x, 3/2–y, 1/2+z; ii) 3/2–x,  
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–1/2+y, 1/2–z), connecting four Ru(II) complexes over an inversion center (Fig. 
2). Furthermore, multiple π–π stacking interactions were observed between the 
aromatic bipyridine rings and the O4-hydrogenpyridine-2,4-dicarboxylate rings 
(ring centroid–centroid distances between 4.218(2) and 5.665(2) Å). 
 
Fig. 2. Part of the crystal packing of the structure of 1, along the c-axis, showing hydrogen 
bonds between the water solvent molecules and the O4-hydrogenpyridine-2,4-dicarboxylate 
groups, with the atom-labeling scheme of the specific atoms involved. Symmetry codes: 
i) 1/2+x, 3/2–y, 1/2+z; ii) 3/2–x, –1/2+y, 1/2–z. 
Electrochemistry 
The electrochemical character of the complex was studied by cyclic voltam-
metry in DMSO at different scan rates (25, 50, 100, 150, 200 and 300 mV s–1) in 
the –2.50 < E < 1.00 V potential range (Fig. 3). The recorded voltammograms 
show a reversible wave at ≈0.30 V vs. Ag/AgCl, which could be readily assigned 
to the Ru(II)/(III) redox couple. The calculated ΔEp values tend to slightly inc-
rease with scan rate (from 100 to 210 mV), indicating the partially reversible 
nature of the redox process. In the region of negative potentials (–2.35 < E < 
< –1.15 V), multiple partially reversible peaks could be observed. This type of 
reductive activity could be assigned to the subsequent reductions of the bipyridyl 
moiety. In comparison to the literature data,30–32 the novel Ru(II) complex shows 
no exceptions concerning its electrochemical behavior. 
Cytotoxic activity 
The antiproliferative activity of the prepared complex was assayed in two 
human cancer cell lines (A549, K562) and non-tumor MRC-5 cells, by the MTT 
assay. The tumor cells were incubated for 72 h with the investigated complex. 
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The results of these tests indicated that the complex after 72 h of incubation 
exhibited no cytotoxic activity with IC50 > 300 μM for A549, and a moderate 
activity with 177.63±2.28 μМ for K562 (Table I). Moreover, the investigated 
complex did not show cytotoxic activity towards non-tumor MRC-5 cells. These 
values are the mean of 2 to 3 independent experiments, whereby the standard 
deviations were less than 15 %. 
 
Fig. 3. The cyclic voltammograms for 1 recorded in DMSO (0.1 mM TBAP) at a glassy 
carbon electrode for scan rates 25, 50, 100, 150, 200 and 300 mV s-1. 
TABLE I. Cytotoxicity of the tested agent in terms of IC50 values (µM) obtained by the MTT 
assay for 72 h of continuous drug action; > 300 denotes that an IC50 value was not obtained in 
the range of concentrations tested up to 300 μM 
Compound A549 K562 MRC-5 
1 > 300 177.63±2.28 > 300 
CONCLUSIONS 
The complex [RuL(bpy)2]PF6·0.5H2O, where L is O4-hydrogenpyridine-2,4- 
-dicarboxylate, was characterized by means of 1H-NMR, elemental analysis, ESI-
MS, IR and single-crystal X-ray analysis. The bidentate ligands are coordinated 
in the cis position, yielding a complex of octahedral geometry. In addition, the 
electrochemical properties of the synthesized complex were investigated and the 
obtained results indicated that its electrochemical behavior was in accordance 
with literature data for Ru(II) complexes. The cytotoxic studies showed that the 
synthesized complex exhibited moderate biological activity towards human 
cancer cell K562, which may be due to the unfavorable ligand dissociation 
kinetics and off-target reactivity, when once in solution. Further research on this 
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topic will be based on the investigation of cytotoxic activity of this compound on 
numerous cancer cell lines and determination of its mode of action. 
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И З В О Д  
НОВИ РУТЕНИЈУМ(II) БИПИРИДИНСКИ КОМПЛЕКС: СИНТЕЗА, 
КАРАКТЕРИЗАЦИЈА И ЦИТОТОКСИЧНОСТ  
AFYA A. BAROUD1, ЉИЉАНА Е. МИХАЈЛОВИЋ-ЛАЛИЋ2, ДАЛИБОР СТАНКОВИЋ2,3, МАРИЈАНА 
КАЈЗЕРБЕРГЕР4, KRISTOF VAN HECKE5, САЊА ГРГУРИЋ-ШИПКА1 и АЛЕКСАНДАР САВИЋ1 
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Пастерова 14, Београд и 5XStruct, Department of Inorganic and Physical Chemistry, Ghent University, 
Krijgslaan 281-S3, B-9000 Ghent, Belgium 
Нови рутенијум(II) бипиридински комплекс са O4-хидроген-пиридин-2,4-
дикарбоксилатом је синтетисан и окарактерисан помоћу IC и NMR спектроскопије, 
масене спектрометрије и рендгенске и елементалне анализе. Електрохемијски карактер 
комплекса је испитан цикличном волтаметријом указивајући на Ru(II)/Ru(III) трансфер 
електрона у опсегу позитивних потенцијала. Насупрот томе, у опсегу негативних 
потенцијала запажени су вишеструки реверзибилни пикови који представљају сукцесив-
не редукције разгранатог бипиридилског дела. Цитотоксична активност комплекса 
испитивана је на две хумане ћелијске линије канцера: A549 (канцер плућа) и K562 
(леукемија) као и на нетуморској ћелијској линији MRC-5, MTT тестом. Добијене IC50 вредности су > 300 и 177,63±2,28 μM за A549 и K562 ћелије, редом. 
(Примљено 9. јануара, ревидирано 18. јануара, прихваћено 23. јануара 2017) 
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